COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,198 Articles (22,713 medRxiv, 8,485 bioRxiv)

Most recent first Previous |  Page 2155: Articles 21541-21550  | Next

Integrated characterization of SARS-CoV-2 genome, microbiome, antibiotic resistance and host response from single throat swabs
Lu, B., Yan, Y., Dong, L., Han, L., Liu, Y., Yu, J., Chen, J., Yi, D., Zhang, M., Wang, C., Wang, R., Wang, D., Wei, H., Liu, D., Yi, C.
10.1101/2020.10.15.340794 — Posted: 2020-10-15
Systematic analysis of innate immune antagonism reveals vulnerabilities of SARS-CoV-2
Hayn, M., Hirschenberger, M., Koepke, L., Straub, J. H., Nchioua, R., Klute, S., Prelli Bozzo, C., Aftab, W., Zech, F., Conzelmann, C., Mueller, J. A., Srinivasachar Badarinarayan, S., Stuerzel, C. M., Forne, I., Stenger, S., Conzelmann, K.-K., Muench, J., Sauter, D., Imhof, A., Kirchhoff, F., Sparrer, K. M. J.
10.1101/2020.10.15.340612 — Posted: 2020-10-15
Evidence of antigenic imprinting in sequential Sarbecovirus immunization
Lv, H., So, R. T. Y., Yuan, M., Liu, H., Lee, C.-C. D., Yip, G. K., Ng, W. W., Wilson, I. A., Peiris, J. S. M., Wu, N. C., Mok, C. K. P.
10.1101/2020.10.14.339465 — Posted: 2020-10-15
The Strand-biased Transcription of SARS-CoV-2 and Unbalanced Inhibition by Remdesivir
Zhao, Y., Sun, J., Li, Y., Li, Z., Xie, Y., Feng, R., Zhao, J., Hu, Y.
10.1101/2020.10.15.325050 — Posted: 2020-10-15
Multiplexed proteomics and imaging of resolving and lethal SARS-CoV-2 infection in the lung
Kalocsay, M., Maliga, Z., Nirmal, A. J., Eisert, R. J., Bradshaw, G. A., Solomon, I. H., Chen, Y.-A., Pelletier, R. J., Jacobson, C. A., Mintseris, J., Padera, R. F., Martinot, A. J., Barouch, D. H., Santagata, S., Sorger, P.
10.1101/2020.10.14.339952 — Posted: 2020-10-15
Inhibition of SARS-CoV-2 viral entry in vitro upon blocking N- and O-glycan elaboration
Yang, Q., Hughes, T. A., Kelkar, A., Yu, X., Cheng, K., Park, S. J., Huang, W.-C., Lovell, J. F., Neelamegham, S.
10.1101/2020.10.15.339838 — Posted: 2020-10-15
A high throughput RNA displacement assay for screening SARS-CoV-2 nsp10-nsp16 complex towards developing therapeutics for COVID-19
Perveen, S., Khalili Yazdi, A., Devkota, K., Li, F., Ghiabi, P., Hajian, T., Loppnau, P., Bolotokova, A., Vedadi, M.
10.1101/2020.10.14.340034 — Posted: 2020-10-15
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
WHO Solidarity Trial Consortium, , Pan, H., Peto, R., Abdool Karim, Q., Alejandria, M., Henao Restrepo, A. M., Hernandez Garcia, C., Kieny, M. P., Malekzadeh, R., Murthy, S., Preziosi, M.-P., Reddy, S., Roses, M., Sathiyamoorthy, V., Rottingen, J.-A., Swaminathan, S.
10.1101/2020.10.15.20209817 — Posted: 2020-10-15 Discussion: Onsite | Offsite
Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols
Chen, P. Z., Bobrovitz, N., Premji, Z., Koopmans, M., Fisman, D. N., Gu, F. X.
10.1101/2020.10.13.20212233 — Posted: 2020-10-15
Physical Activity Decreases the Prevalence of COVID-19-associated Hospitalization: Brazil EXTRA Study
Souza, F. R., Motta-Santos, D., Soares, D. d. S., Lima, J. B., Cardozo, G. G., Guimaraes, L. S. P., Negrao, C. E., dos Santos, M. R.
10.1101/2020.10.14.20212704 — Posted: 2020-10-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).